Hyperactivated CDK4/6 has been reported in many human cancers as a result of overexpression of cyclin D, inactivation of INK4 and CIP/KIP inhibitors or deletion and/or epigenetic alterations of RB 68. This evidence concerns the gene RB1 and cancer.